Tularik Inc. (TLRK) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Tularik Inc. (TLRK)

An SI Board Since October 1999

Posts	SubjectMarks	Bans	Symbol
598	27	0	TLRK

Emcee: scaram(o)uche	Type: Unmoderated

Introduction Market Data Compact

for commentary re. Tularik, its projects, competititors, etc......

Friday October 15, 7:29 pm Eastern Time

Drugmaker Tularik files to raise $69 mln in IPO

WASHINGTON, Oct 15 (Reuters) - Tularik Inc., a company seeking to develop drugs to
treat cancer, diabetes and other diseases, filed Friday with regulators to raise about $69
million in an initial public offering.

The company, based in San Francisco, research and develop drugs to treat cancer, bacterial
diseases, obesity, inflammation and immune disorders.

Tularik plans to sell 6.25 million shares in a projected range of $11-$13 per share in the IPO, according to the prospectus filed
with the Securities and Exchange Commission.

The company expects to raise an estimated $69.25 million in net proceeds in the IPO which it plans to use for research and
development as well as general corporate purposes.

The company has established and said it plans to continue to pursue collaborations with selected pharmaceutical and
biotechnology companies, including Merck and Co. Inc. (NYSE:MRK - news) and Knoll Inc. (NYSE:KNL - news), among
others.

The drugs it produces would have to receive approval from the U.S. Food and Drug Administration before commercial use, the
company said.

Tularik had $11.9 million in research and development revenue during the first six months of 1999 and posted $9.8 million in
net losses, the filing said.

After the offering, there will be about 41.3 million shares outstanding in the company, according to the filing.

David Goeddel, 48, has been the company's chief executive officer since April 1996 and helped found the company in 1991.

The underwriters, Lehman Brothers, Hambrecht & Quist, J.P. Morgan & Co. and Warburg Dillon Read LLC, have been
granted 937,500 extra shares in the event of heavy demand.

The company has applied to sell its shares on Nasdaq under the symbol ''TLRK.''

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
598	Thanks again Rick, Wilder & Tuck. The gift that keeps giving. AMGN at $129	mopgcw	-	7/30/2014
597	I'm good, thanks! And you're welcome, for whatever you're thanking	scaram(o)uche	-	8/29/2013
596	and thank you rick... ;) hope all is well.	mopgcw	-	8/26/2013
595	thank you tularik....	mopgcw	-	8/26/2013
594	J Bacteriol. 2007 Jul 20; [Epub ahead of print] A novel indole compound that in	scaram(o)uche	-	7/31/2007
593	Bioinformatics. 2005 Apr 6; [Epub ahead of print] Multiclass cancer classifica	scaram(o)uche	-	4/10/2005
592	>> Didn't waste anytime in pulling the plug on x67, did they? <<	scaram(o)uche	-	9/29/2004
591	Thanks for the pointer. Didn't waste anytime in pulling the plug on x67, di	keokalani'nui	-	9/29/2004
590	Amgen website will be updated every six months re. pipeline. Roger Perlmutter g	scaram(o)uche	-	9/29/2004
589	[Antagonistic antibody prevents toll-like receptor 2–driven lethal shock-like sy	tuck	-	5/25/2004
588	GS: TLRK (NR/N): 1Q 2004 Results in line, multiple data points in 2004 52-Week	mopgcw	-	4/26/2004
587	GS: AMGN(OP/N)/TLRK (NR/N): AMGN to acquire TLRK for $1.3 billion Amgen and Tu	mopgcw	-	3/30/2004
586	And congrats to all shareholders! Rick	scaram(o)uche	-	3/29/2004
585	Sigh. Some day, it's all going to come together. :-) This was a great rid	scaram(o)uche	-	3/29/2004
584	Great call on the "T131 partnership", right. I've changed my mind	keokalani'nui	-	3/29/2004
583	>> 8 days within which to announce a t131 pship << quite an interes	scaram(o)uche	-	3/29/2004
582	I hope you did buy those calls, Wilder	tom pope	-	3/29/2004
581	I can see no other reason to drive it at this point. I should not complain to	mopgcw	-	3/29/2004
580	a GREAT move for Amgen (eom).	scaram(o)uche	-	3/29/2004
579	too cheap. alas.	mopgcw	-	3/29/2004
578	Congrats longs. Best of Luck, SS >>> Message 19961844	SnowShredder	-	3/29/2004
577	>>8:57AM TLRK halted, news pending << Cheers, Tuck	tuck	-	3/29/2004
576	GS: TLRK (IL/N): Update with management, multiple 2004 milestones on track 52-W	mopgcw	-	3/28/2004
575	liquidity in the TLRK options is not very good, Wilder. Good idea, though	tom pope	-	3/24/2004
574	Yes! I usually don't do so good with options, btw. Or shorting. Or....	keokalani'nui	-	3/23/2004

Go to reply# or date (mm/dd/yy):